C. Corcoran

发表

Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling.

L. O’Driscoll, S. Rani, K. O’Brien, 2011, Methods in molecular biology.

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.

L. O’Driscoll, S. Rani, C. Corcoran, 2014, Cancer research.

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

A. Kohlmann, C. Corcoran, A. Sharpe, 2016, PloS one.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

F. Saad, N. Agarwal, C. Corcoran, 2020, The New England journal of medicine.

Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.

L. O’Driscoll, C. Corcoran, 2015, Methods in molecular biology.

Intracellular and extracellular microRNAs in breast cancer.

L. O’Driscoll, M. Duffy, C. Corcoran, 2011, Clinical chemistry.

Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes

L. O’Driscoll, S. Rani, K. O’Brien, 2012, PloS one.

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity

L. O’Driscoll, S. Rani, K. O’Brien, 2015, Oncotarget.

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

N. Agarwal, J. Barrett, C. Corcoran, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

J. Barrett, J. Schellens, P. Elvin, 2017, Clinical Cancer Research.

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

L. O’Driscoll, C. Corcoran, J. Crown, 2010, Breast Cancer Research and Treatment.

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

B. Taylor, S. Chandarlapaty, J. Baselga, 2020, Clinical Cancer Research.

Relevance of Circulating Tumor Cells , Extracellular Nucleic Acids and Exosomes in 1 Breast Cancer 2 3

L. O’Driscoll, C. Corcoran, J. Crown, 2019 .

1 School of Pharmacy and Pharmaceutical Sciences & Molecular Therapeutics for Cancer

L. O’Driscoll, C. Corcoran, J. Crown, 2010 .

miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression

Sweta Rani, L. O’Driscoll, S. Rani, 2014, The Prostate.

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

N. Agarwal, C. Corcoran, O. Sartor, 2020, Annals of Oncology.

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

L. O’Driscoll, S. Rani, C. Corcoran, 2011, Molecular Cancer.

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients

A. Kohlmann, C. Corcoran, G. Schiavon, 2017, PloS one.

Honeydew Collecting in Malagasy Stingless Bees (Hymenoptera: Apidae: Meliponini) and Observations on Competition with Invasive Ants

C. Corcoran, H. Koch, M. Jonker, 2011 .

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

K. Tamura, C. Corcoran, G. Schiavon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.

L. O’Driscoll, L. Hughes, S. Rani, 2013, European journal of cancer.

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

A. Kohlmann, C. Gedye, C. Corcoran, 2019, Annals of Oncology.

Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

B. Taylor, S. Chandarlapaty, J. Baselga, 2018 .

Neuromedin U: A Candidate Biomarker and Therapeutic Targetto Predict and Overcome Resistance to HER-Tyrosine

L. O’Driscoll, S. Rani, C. Corcoran, 2015 .

The use of LC‐MS to identify differentially expressed proteins in docetaxel‐resistant prostate cancer cell lines

L. O’Driscoll, M. Henry, P. Meleady, 2012, Proteomics.

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

L. O’Driscoll, S. Rani, C. Corcoran, 2014, Molecular Cancer.

Design, Synthesis and Biological Evaluation of a Novel Bioactive Indane Scaffold 2-(diphenylmethylene)c-2,3-dihydro-1H-inden-1-one with Potential Anticancer Activity.

L. O’Driscoll, M. Ruether, C. Corcoran, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

A. Kohlmann, C. Gedye, C. Corcoran, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.

C. Corcoran, A. Barnicle, E. Harrington, 2021 .

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.

F. Saad, A. Kohlmann, J. Bono, 2020 .